SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lieberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:14371443.
  • 2
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:15351541.
  • 3
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:20772082.
  • 4
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chestnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:13441352.
  • 5
    Reginster J-Y, Minne H, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:8391.
  • 6
    McClung MR, Geusons P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Damond T, Eastell R, Meunier PJ, Reginster JY, for the Hip Intervention Program Study Group 2001 Effect of risedronate and the risk of hip fracture in elderly women. N Eng J Med 344:333339.
  • 7
    Bauer W, Aub JC, Albricht F 1929 Studies of calcium phosphorus metabolisms: Study of bone trabeculae as ready available reserve supply of calcium. J Exp Med 49:145162.
  • 8
    Selye H 1932 On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol. Endocrinology 16:547558.
  • 9
    Cosman F, Lindsay R 1998 Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 62:475480.
  • 10
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550556.
  • 11
    Finkelstein J, Klibanksi A, Arnold A, Toth T, Hornstein M, Neer R, 1998 Prevention of estrogen deficiency—related bone loss with human parathyroid hormone-(1-34). JAMA 280:10671073.
  • 12
    Lindsay R, Hodsman A, Genant H, Bolognese M, Ettinger M 1998 A randomized controlled multi-center study of 1-84hPTH for treatment of postmenopausal osteoporosis. Bone 23(Suppl):175.
  • 13
    Lane NE, Sanchez S, Modin G, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical. J Clin Invest 102:16271633.
  • 14
    Kurland E, Cosman F, McMahon D, Rosen C, Lindsay R, Bilezikian J 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. JCEM 859:30693076.
  • 15
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620628.
  • 16
    Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M 1999 Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296306.
  • 17
    Segre GV 1983 Amino terminal radioimmunoassays for human PTH. In: FrameB, PottsJTJr (eds.) Clinical Disorders of Bone and Mineral Metabolism. Excerpta Medica, Amsterdam, The Netherlands, p. 14.
  • 18
    Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR 1998 The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Int Med 128:793809.
  • 19
    Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR 1999 Vertebral fractures and mortality in older women. Arch Intern Med 159:12151220.
  • 20
    Hall SE, Criddle RA, Comito TL, Prince RL 1999 A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508515.
  • 21
    Neer RM, Arnaud C, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Mellstrom D, Ish-Shalom S, Oefjord ES, Marcinowsak-Suchowierska E, Salmi J, Gaspar L, Mulder H, Halse J, Sawicki AZ, Genant H, Wang O, Mitlak BH 2000 Recombinant human PTH [rhPTH(1-34)] reduces the risk of spine and non-spine fractures in postmenopausal osteoperosis. Endocr Soc June abstract 19342.
  • 22
    Roe EB, Sanchez SD, del Puerto GA, Pierini E, Bacchetti P, Cann CE, Arnaud CD 1999 Parathyroid hormone 1-34(hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis—results from a placebo-controlled randomized trial. J Bone Miner Res 14:S1;S137.
  • 23
    Finkelstein JS, Arnold AL 1999 Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 84:12141219.
  • 24
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 15:944951.
  • 25
    Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R 1998 Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner 13:10511055.
  • 26
    Hodsman AB 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiscent cancellous surface. Bone 14:523527.
  • 27
    Schmidt IU, Dobnig H, Turner RT 1995 Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 136:51275134.
  • 28
    Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone line cells. Endocrinology 136:36323638.
  • 29
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439446.